Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ficlatuzumab + Gefitinib in Asian NSCLC
NCT01039948Phase 2Completed
- Sponsor
- AVEO Oncology
- Start
- Dec 2009
- Primary completion
- Aug 2013
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of ficlatuzumab in non-small cell lung cancer (NSCLC), sponsored by AVEO Oncology. Started Dec 2009; status: completed.
02
Drugs
ficlatuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01039948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01039948.